Connor, Clark & Lunn Investment Management (CC&L)’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $11.3M | Buy |
|
|||||
|
2025
Q1 | $7.82M | Buy |
|
|||||
|
2024
Q4 | $4.77M | Sell |
|
|||||
|
2024
Q3 | $5.19M | Sell |
|
|||||
|
2024
Q2 | $4.84M | Buy |
|
|||||
|
2024
Q1 | $3.65M | Buy |
|
|||||
|
2023
Q4 | $4.14M | Buy |
|
|||||
|
2023
Q3 | $3.84M | Buy |
|
|||||
|
2023
Q2 | $2.82M | Buy |
|
|||||
|
2023
Q1 | $2.9M | Buy |
|
|||||
|
2022
Q4 | $319K | Buy |
|
|||||
|
2022
Q2 | – | Sell |
|
|||||
|
2022
Q1 | $1.5M | Buy |
|
|||||
|
2021
Q3 | – | Sell |
|
|||||
|
2021
Q2 | $764K | Buy |
|
|||||
|
2020
Q2 | – | Sell |
|
|||||
|
2020
Q1 | $1.22M | Buy |
|
|||||
|
2019
Q4 | $612K | Buy |
|
|||||
|
2018
Q2 | – | Sell |
|
|||||
|
2018
Q1 | $78K | Sell |
|
|||||
|
2017
Q4 | $184K | Sell |
|
|||||
|
2017
Q3 | $256K | Buy |
|
|||||
|
2016
Q3 | – | Sell |
|
|||||
|
2016
Q2 | $378K | Sell |
|
|||||
|
2016
Q1 | $570K | Sell |
|
|||||
|
2015
Q4 | $2.13M | Sell |
|
|||||
|
2015
Q3 | $2.72M | Buy |
|
|||||
|
2015
Q2 | $1.35M | Sell |
|
|||||
|
2015
Q1 | $1.45M | Sell |
|
|||||
|
2014
Q4 | $2.59M | Buy |
|
|||||
|
2014
Q3 | $1.66M | Buy |
|
|||||
|
2014
Q2 | $2.03M | Sell |
|
|||||
|
2014
Q1 | $6.17M | Buy |
|
|||||
|
2013
Q4 | $2.56M | Buy |
|
|||||
|
2013
Q3 | – | Sell |
|
|||||
|
2013
Q2 | $183K | Buy |
|